Center for Molecular Cardiology, University of Zürich, Wagistrasse 12, 8952 Schlieren, Switzerland.
Department of Cardiac Surgery, University Heart Center, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland.
Cardiovasc Res. 2023 Oct 16;119(12):2190-2201. doi: 10.1093/cvr/cvad102.
Enhancing SIRT1 activity exerts beneficial cardiovascular effects. In diabetes, plasma SIRT1 levels are reduced. We aimed to investigate the therapeutic potential of chronic recombinant murine SIRT1 (rmSIRT1) supplementation to alleviate endothelial and vascular dysfunction in diabetic mice (db/db).
Left internal mammary arteries obtained from patients undergoing coronary artery bypass grafting with or without a diagnosis of diabetes were assayed for SIRT1 protein levels. Twelve-week-old male db/db mice and db/+ controls were treated with vehicle or rmSIRT1 intraperitoneally for 4 weeks, after which carotid artery pulse wave velocity (PWV) and energy expenditure/activity were assessed by ultrasound and metabolic cages, respectively. Aorta, carotid, and mesenteric arteries were isolated to determine endothelial and vascular function using the myograph system.Arteries obtained from diabetic patients had significantly lower levels of SIRT1 relative to non-diabetics. In line, aortic SIRT1 levels were reduced in db/db mice compared to db/+ mice, while rmSIRT1 supplementation restored SIRT1 levels. Mice receiving rmSIRT1 supplementation displayed increased physical activity and improved vascular compliance as reflected by reduced PWV and attenuated collagen deposition. Aorta of rmSIRT1-treated mice exhibited increased endothelial nitric oxide (eNOS) activity, while endothelium-dependent contractions of their carotid arteries were significantly decreased, with mesenteric resistance arteries showing preserved hyperpolarization. Ex vivo incubation with reactive oxygen species (ROS) scavenger Tiron and NADPH oxidase inhibitor apocynin revealed that rmSIRT1 leads to preserved vascular function by suppressing NADPH oxidase (NOX)-related ROS synthesis. Chronic rmSIRT1 treatment resulted in reduced expression of both NOX1 and NOX4, in line with a reduction in aortic protein carbonylation and plasma nitrotyrosine levels.
In diabetic conditions, arterial SIRT1 levels are significantly reduced. Chronic rmSIRT1 supplementation improves endothelial function and vascular compliance by enhancing eNOS activity and suppressing NOX-related oxidative stress. Thus, SIRT1 supplementation may represent novel therapeutic strategy to prevent diabetic vascular disease.
增强 SIRT1 活性对心血管有益。在糖尿病患者中,血浆 SIRT1 水平降低。我们旨在研究慢性重组鼠 SIRT1(rmSIRT1)补充对改善糖尿病小鼠(db/db)内皮和血管功能障碍的治疗潜力。
从接受冠状动脉旁路移植术的患者体内获取左侧内乳动脉,这些患者中有的患有糖尿病,有的没有。12 周龄雄性 db/db 小鼠和 db/+ 对照小鼠接受腹膜内注射载体或 rmSIRT1 4 周,然后通过超声和代谢笼分别评估颈动脉脉搏波速度(PWV)和能量消耗/活性。分离主动脉、颈动脉和肠系膜动脉,使用肌动描记系统测定内皮和血管功能。与非糖尿病患者相比,糖尿病患者的动脉中 SIRT1 水平明显降低。与此一致,db/db 小鼠的主动脉 SIRT1 水平较 db/+ 小鼠降低,而 rmSIRT1 补充恢复了 SIRT1 水平。接受 rmSIRT1 补充的小鼠表现出更高的体力活动,并改善了血管顺应性,表现为 PWV 降低和胶原沉积减少。rmSIRT1 处理的小鼠的主动脉显示出增加的内皮一氧化氮合酶(eNOS)活性,同时其颈动脉的内皮依赖性收缩显著降低,肠系膜阻力动脉表现出保留的超极化。用活性氧(ROS)清除剂 Tiron 和 NADPH 氧化酶抑制剂 apocynin 进行的离体孵育表明,rmSIRT1 通过抑制 NADPH 氧化酶(NOX)相关的 ROS 合成来维持血管功能。慢性 rmSIRT1 治疗导致 NOX1 和 NOX4 的表达减少,与主动脉蛋白羰基化和血浆硝基酪氨酸水平降低一致。
在糖尿病状态下,动脉 SIRT1 水平显著降低。慢性 rmSIRT1 补充通过增强 eNOS 活性和抑制 NOX 相关的氧化应激来改善内皮功能和血管顺应性。因此,SIRT1 补充可能代表预防糖尿病血管疾病的新治疗策略。